Skip to content

A Randomized, Double Blind, Controlled Trial for the Effect of Yueju Pill in The Treatment of Patient with Depression

A Randomized, Double Blind, Controlled Trial for the Effect of Yueju Pill in The Treatment of Patient with Depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021114
Enrollment
Unknown
Registered
2019-01-29
Start date
2016-06-01
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

Group 1:YUEJU PILL 12g/day+placebo
Group 2:YUEJU PILL 23g/day(week1)12g/day(week2-4)+placebo
Group 3:ESCITALOPRAM 10mg/day+placebo

Sponsors

The Fourth People's Hospital of Taizhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic criteria for DSM-V depression; 2) Aged 18-75 years old; 3) Hamilton Depression Scale (24 items) score HAMD-24 = 20 points; Montgomery Depression Rating Scale score MADRS = 12 points; 4) Chinese medicine (including Chinese herbal medicines and medicinal herbs and decoctions), Western medicine (Prozac, Lai Shi Pu, Bolexin, etc.) have not been used in the past 1 week, or in the short term (3-5) Those who have taken the above drugs within days) have been deactivated for more than 7 days; 5) Those who are willing to accept 30 days of treatment, informed consent, and signed informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with suicidal depression, the third score of the Hamilton Depression Scale = 2 points; 2) Those who are suffering from other mental illnesses other than depression, as well as those caused by external environmental disturbances or traumatic brain injury; 3) pregnant or lactating women; 4) Those with a history of drug allergy; 5) Patients with severe primary diseases such as cardiovascular, pulmonary, liver and kidney and hematopoietic system, and severe brain organic diseases and mental illnesses; 6) Alcohol and/or psychoactive substances, drug abusers and dependents (including sleeping pills); 7) Those who do not meet the inclusion criteria, do not use the drugs according to the regulations, can not judge the efficacy or safety of the data and other factors affecting the efficacy and safety. 8) Those who cannot understand the scale content due to lack of consciousness, language barrier, intelligence and cultural level.

Design outcomes

Primary

MeasureTime frame
HAMD-24;QIDS-16;PHQ-9;Stagnation syndrome TCM syndrome differentiation scale;TCM constitution classification and judgment self test;

Countries

China

Contacts

Public ContactCHEN GANG

Nanjing University of Traditional Chinese Medicine

hdn_2001@126.com+86 13160069798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026